Wire · opportunities
Lilly's obesity pill Foundayo 'disappointed' in Q2, as injectables continue to boom
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 31 August 2026 · Fusion42 review
Eli Lilly's oral GLP-1 obesity drug Foundayo reported $98 million in Q2 sales, significantly lagging behind Novo Nordisk's Wegovy, which reached $497 million. However, Lilly's injectable obesity and diabetes treatments Mounjaro and Zepbound continue to see very strong sales growth.
This Wire brief sits within Fusion42's coverage of Health.
◆ ◆ The Wire takeaway
Lilly’s injectable diabetes and obesity drugs are dominating new patient starts, reshaping market share despite Foundayo's slower start. If you build obesity or diabetes treatments, position your sales and marketing where patient uptake clearly leads to sustained growth.
◆ Coverage
1 source · 5 Aug 2026
◆ Related on Wire
◆ Topics